N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Woodsmoke Particulate + Prednisone
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -2.62; 5.45 percent neutrophils — p=0.24
Phase 2 N=34 Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Lung Cancer · Lung Metastases
Primary: Number of Patients Who Are Free From Pulmonary Exacerbations — 72; 40 percental of participants
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Early Phase 1 N=22 Quantifying Airway Inflammation With Radiologic Tests
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
Phase 2 N=10 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Phase 2 N=43 Mitigation of Radiation Pneumonitis and Fibrosis
Lung Cancer · Radiation Pneumonitis
Primary: Number of Participants With Radiation Pneumonitis — 8; 10 participants — p=0.05
Phase 2 N=9 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
IPF
Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants
Phase 2 N=39 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Accelerated Phase Chronic Myelogenous Leukemia · Blastic Phase Chronic Myelogenous Leukemia · Childhood Acute Lymphoblastic Leukemia in Remission
Primary: Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28. — 20; 8 participants
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
Phase 3 N=37 Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)
Pneumonia · Idiopathic Pneumonia Syndrome
Primary: Response Rate — 62.5; 66.7 percentage of participants
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
N/A N=74 Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
Kerosene Pneumonitis
Primary: Treatment Failure — 3; 2 participants — p=>0.50
Phase 1 N=24 A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 66.7; 77.8; 50.0; 0 percentage of participants
Phase 2 N=58 Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Serum MMP7 Level — -0.15; 0.88 ng/ml — p=0.2072
Phase 3 N=584 Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Phase 2 N=181 Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
Non-Small-Cell Lung Carcinoma
Primary: The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) — 2; 0…
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
N/A N=9 Woodsmoke Particulate + Hypertonic Saline
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -0.04; -0.5 percent neutrophils — p=> 0.99
Phase 3 N=25 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
Interstitial Pneumonitis · Polymyositis · Dermatomyositis
Primary: Overall Survival — 88.0 percentage of participants
N/A N=203 The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly
Pneumonia
Primary: Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) — 10; 3; 4; 34 Participants
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=34 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Interstitial Pneumonitis
Primary: Change in 6-minute Walk Test Distance (6MWD) — 46.5; 23.2 Meters
N/A N=154 Oropharyngeal Dysphagia in Patients With Community Acquired Pneumonia
Dysphagia · Pneumonia
Primary: Intra Hospital Mortality — 7; 0 Participants
Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]